Gabapentin + Gabapentin + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Transient Insomnia
Conditions
Transient Insomnia
Trial Timeline
Oct 1, 2004 → Nov 1, 2004
NCT ID
NCT00666770About Gabapentin + Gabapentin + Placebo
Gabapentin + Gabapentin + Placebo is a phase 3 stage product being developed by Pfizer for Transient Insomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT00666770. Target conditions include Transient Insomnia.
What happened to similar drugs?
0 of 8 similar drugs in Transient Insomnia were approved
Approved (0) Terminated (0) Active (8)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00674752 | Phase 3 | Completed |
| NCT00666770 | Phase 3 | Completed |
| NCT00667108 | Phase 3 | Completed |
| NCT00666939 | Phase 3 | Completed |
Competing Products
10 competing products in Transient Insomnia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2624803 - Capsules + Zolpidem - Tablets + Placebo - Capsules + Placebo - Tablets | Eli Lilly | Phase 1 | 29 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 40 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 40 |
| Gabapentin + Placebo | Pfizer | Phase 3 | 40 |
| Gabapentin + Gabapentin + Placebo | Pfizer | Phase 3 | 40 |
| Gabapentin | Pfizer | Phase 3 | 40 |
| Gabapentin + Placebo | Pfizer | Phase 3 | 40 |
| Milvexian + Placebo | Bristol Myers Squibb | Phase 3 | 47 |
| Apixaban + Warfarin | Bristol Myers Squibb | Phase 3 | 40 |
| Levosimendan + Placebo | Orion Corporation | Phase 2 | 32 |